In a significant move last night, President Donald J. Trump introduced TrumpRx.gov, a groundbreaking government initiative designed to provide Americans with direct access to substantially reduced prices on a variety of commonly prescribed, high-cost brand-name medications. These reductions were made possible through pioneering Most-Favored-Nation pricing agreements established with major pharmaceutical companies, ensuring that American prices align with the lowest available in other developed countries. This initiative aims to put an end to years of excessive spending on medications and provide immediate financial relief to consumers.
Beginning today, American patients, particularly the millions facing steep out-of-pocket expenses for medications not fully covered by their insurance plans, can take advantage of significantly lower prices on a wide range of essential medications through TrumpRx.gov. The Trump Administration is committed to securing optimal deals for the American populace, with plans to continuously expand the selection of high-cost medications available at reduced prices.
Key examples of the savings include:
GLP-1 medications, which rank among the highest-expense drugs in the United States, will see substantial price cuts on TrumpRx.gov.
- The monthly cost of Ozempic® and the injectable Wegovy® will be reduced from $1,028 and $1,349, respectively, to an average of $350 and as low as $199, depending on the prescribed dosage.
- The monthly price of the Wegovy® pill will drop from $1,349 to as low as $149, again depending on dosage.
- The monthly price of Zepbound® will decrease from $1,088 to an average of $346, with possible prices as low as $299 depending on dosage.
For millions of Americans grappling with infertility, often forced to pay for fertility treatments entirely out of pocket, TrumpRx.gov promises average savings exceeding $2,000 per treatment cycle on commonly used medications.
- The price of Gonal-F®, a widely utilized fertility medication, will be reduced to as low as $168 per pen, contingent on dosage.
- The price of Cetrotide®, another frequently prescribed fertility drug, will plummet from $316 to just $22.50.
- The price of Ovidrel® will see a reduction from $251 to $84.
This launch marks merely the beginning.
The Trump Administration plans to onboard additional pharmaceutical companies under Most-Favored-Nation agreements and is proactively seeking further partnerships to expand the platform, which is expected to drive even greater savings for Americans on prescription medications.
For those Americans who receive their prescriptions through insurance, President Trump urges Congress to swiftly pass his Great Healthcare Plan. This comprehensive reform aims to solidify the savings from the Most-Favored-Nation initiative, reduce insurance premiums, hold large insurers accountable, maximize price transparency, and allow coverage of purchases made through TrumpRx.gov under health plans. Such measures are designed to ensure that every American can benefit from these historic reductions in drug costs.
